Restoration and regeneration of failing myocardium with cell transplantation and tissue engineering.
Cell transplantation and the creation of bioengineered cardiovascular tissues are novel biologic approaches to restore and regenerate failing myocardium. These rapidly evolving therapies may complement and enhance other mechanical and surgical interventions for patients with congestive heart failure, providing cardiac surgeons with a wider range of treatments for patients at risk of congestive heart failure. Proof-of-concept studies have been performed in several experimental animal models of human cardiovascular disease, such as myocardial infarction and dilated cardiomyopathy. Although the exact mechanisms are unclear, cell transplantation restores cardiac function and limits ventricular dilatation. Clinical cell transplantation has been performed in a limited number of patients with encouraging preliminary results. In contrast, bioengineered muscle grafting is largely experimental but offers the promise of myocardial regeneration by replacing irreversibly damaged myocardium with healthy autologous tissue to facilitate more extensive ventricular remodeling surgery.
Fedak
Paul W M
PW
Division of Cardiac Surgery, Toronto General Hospital, Toronto, Ontario M5G 2C4, Canada.
Weisel
Richard D
RD
Verma
Subodh
S
Mickle
Donald A G
DA
Li
Ren-Ke
RK
D000818:Animals; D017690:Cell Transplantation / Q000379:methods*; D006333:Heart Failure / Q000473:pathology* / Q000628:therapy*; D006801:Humans; D032446:Myoblasts / Q000473:pathology / Q000637:transplantation; D009203:Myocardial Infarction / Q000628:therapy; D017202:Myocardial Ischemia / Q000628:therapy; D009206:Myocardium / Q000473:pathology*; D023822:Tissue Engineering / Q000379:methods*